USNANYSEMedicinal Chemicals & Botanical ProductsFiscal year ends January 3
USANA HEALTH SCIENCES INC
Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 13, 2026
$14.89−0.65 (-4.18%)
Close on Oct 19, 2026
- Market cap
- $275.26M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$6.00 (−28.72%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
USANA HEALTH SCIENCES INC grew revenue 1.6% to $913.36M over the twelve months to Jul 4, 2026. Operating income fell 101.9% to -$1.08M, moving the operating margin from 6.2% to -0.1%. Free cash flow was $15.93M, down 68.7% from a year earlier.
Revenue
$913.36M
+1.6% vs. a year earlier
Operating income
-$1.08M
-101.9% vs. a year earlier
Free cash flow
$15.93M
-68.7% vs. a year earlier
EPS, diluted
-$1.21
-167.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 4, 2026
Valuation
- Market cap
- $275.26M
- P/E ratio
- –
- Price to sales
- 0.30
- Price to book
- 0.52
- Dividend yield
- –
- Free cash flow yield
- 5.79%
Fundamentals
- Revenue
- $913.36M
- Net income
- -$22.16M
- EPS, diluted
- -$1.21
- Free cash flow
- $15.93M
- Book value per share
- $28.47
- Diluted shares
- 18M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$913.36M+1.6% YoY
Gross profit
$707.36M-1.6% YoY
Operating income
-$1.08M-101.9% YoY
Net income
-$22.16M-165.0% YoY
EPS, diluted
-$1.21-167.2% YoY
Free cash flow
$15.93M-68.7% YoY
Reported periodTrailing twelve months